Abstract
Primary ciliary dyskinesia (PCD) is a rare genetic disease that causes recurrent respiratory infections. People with PCD may be at high risk of severe COVID-19 and vaccination against SARS-CoV-2 is therefore important. We studied vaccination willingness, speed of vaccination uptake, side effects, and changes in social contact behavior after vaccination in people with PCD. We used data from COVID-PCD, an international participatory cohort study. A questionnaire was e-mailed to participants in May 2021 that asked about COVID-19 vaccinations. 423 participants from 31 countries replied (median age: 30 years; 261 (62%) female). Vaccination uptake and willingness was high with 273 of 287 adults (96%) being vaccinated or willing to be in June 2021; only 4% were hesitant. The most common reasons for hesitancy were fear of side effects (reported by 88%). Mild side effects were common but no participant reported severe side effects. Half of participants changed their social contact behaviour after vaccination by seeing friends and family more often. The high vaccination willingness in the study population might reflect the extraordinary effort taken by PCD support groups to inform people about COVID-19 vaccination. Clear and specific public information and involvement of representatives is important for high vaccine uptake.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04602481
Funding Statement
This research was funded by the Swiss National Foundation (SNF 320030B_192804/1, PZ00P3_185923), Switzerland, the Swiss Lung Association, Switzerland (2021-08_Pedersen), the PCD Foundation, United States; the Verein Kartagener Syndrom und Primaere Ciliaere Dyskinesie, Germany; the PCD Family Support Group, UK; and PCD Australia, Australia. Study authors participate in the BEAT-PCD Clinical Research Collaboration, supported by the European Respiratory Society.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Bern Cantonal Ethics Committee (Kantonale Ethikkomission Bern) has approved this study (Study ID: 2020-00830) and the research was performed in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
eva.pedersen{at}ispm.unibe.ch (E.P), maria.mallet{at}ispm.unibe.ch (C.M.), yin.lam{at}ispm.unibe.ch (Y.L), Myrofora.goutaki{at}ispm.unibe.ch (M.G.), Claudia.kuehni{at}ispm.unibe.ch (C.K.).
saradcp{at}virgilio.it
icizeau{at}cegetel.net
fiona.copeland{at}stonac.co.uk
asociaciondcpes{at}gmail.com
michelemanion{at}gmail.com
Amanda-lea.harris{at}uhs.nhs.uk
jlucas1{at}soton.ac.uk
santamar{at}unina.it
Data Availability
COVID-PCD data can be made available on reasonable request by contacting Claudia Kuehni by email: Claudia.kuehni{at}ispm.unibe.ch.
